Search

Displaying results 9321 - 9330 of 10000 in total
  1. Drug

    Safflower

    go.drugbank.com/drugs/DB10905
    Approved

    Safflower allergenic extract is used in allergenic testing.

  2. Drug

    Cocoa

    go.drugbank.com/drugs/DB10977
    Approved

    Cocoa allergenic extract is used in allergenic testing.

  3. Drug

    Sage

    go.drugbank.com/drugs/DB10982
    Approved

    Sage allergenic extract is used in allergenic testing.

  4. Drug

    Garlic

    go.drugbank.com/drugs/DB10532
    ApprovedNutraceutical

    Garlic allergenic extract is used in allergenic testing.

  5. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  6. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector cells. It is developed for the tr...

  7. Drug

    Milvexian

    go.drugbank.com/drugs/DB16233
    Investigational

    Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).

  8. Drug

    Padsevonil

    go.drugbank.com/drugs/DB14977
    Investigational

    Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).

  9. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).

  10. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).